Teva Pharma Launches AHZANTIVE Biosimilar to Eylea in Europe
Teva has launched AHZANTIVE (aflibercept), an EMA-approved biosimilar to Eylea, across Europe. Demonstrating comparable efficacy, safety, and immunogenicity to the reference product, the launch expands Teva’s biosimilars and ophthalmology portfolio while supporting its long-term Pivot to Growth strategy.
Yolanda Tibbe | 06/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy